{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:33Z","timestamp":1787003673533,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"PUTI grant awarded Universitas Indonesia","award":["NKB-122\/UN2.RST\/HKP.05.00\/2023"],"award-info":[{"award-number":["NKB-122\/UN2.RST\/HKP.05.00\/2023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13931-2","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T20:19:39Z","timestamp":1755029979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quality-of-life changes six months after the programmatic switch from nevirapine to dolutegravir-based ART in stable PLWH: a prospective cohort study in Indonesia"],"prefix":"10.1038","volume":"15","author":[{"given":"Meivina Ramadhani","family":"Pane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evy","family":"Yunihastuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi","family":"Putranto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina","family":"Widhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukamto","family":"Koesnoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzah","family":"Shatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imam","family":"Subekti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"13931_CR1","unstructured":"HIV Drug Resistance Report 2021. (Geneva: World Health Organization, (2021)."},{"key":"13931_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s40506-019-00203-7","volume":"11","author":"A Kolakowska","year":"2019","unstructured":"Kolakowska, A., Maresca, A. F., Collins, I. J. & Cailhol, J. Update on adverse effects of HIV integrase inhibitors. Curr. Treat. Options Infect. Dis. 11, 372\u2013387 (2019).","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"13931_CR3","doi-asserted-by":"publisher","first-page":"e25899","DOI":"10.1002\/jia2.25899","volume":"25","author":"AL Esber","year":"2022","unstructured":"Esber, A. L. et al. Weight gain during the dolutegravir transition in the African cohort study. J. Int. AIDS Soc. 25, e25899 (2022).","journal-title":"J. Int. AIDS Soc."},{"key":"13931_CR4","first-page":"13","volume":"20","author":"JC Yombi","year":"2018","unstructured":"Yombi, J. C. Dolutegravir neuropsychiatric adverse events: specific drug effect or class effect. AIDS Rev. 20, 13\u201325 (2018).","journal-title":"AIDS Rev."},{"key":"13931_CR5","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.3390\/v14112558","volume":"14","author":"KH Lee","year":"2022","unstructured":"Lee, K. H. et al. Real-World effectiveness, tolerability, and safety of dolutegravir\/lamivudine in Korea. Viruses 14, 2558 (2022).","journal-title":"Viruses"},{"key":"13931_CR6","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s43440-023-00515-y","volume":"75","author":"A Jakimiuk","year":"2023","unstructured":"Jakimiuk, A., Piechal, A., Wierci\u0144ska-Drapa\u0142o, A. & Nowaczyk, A. Mirowska-Guzel, D. Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies. Pharmacol. Rep. 75, 1138\u20131151 (2023).","journal-title":"Pharmacol. Rep."},{"key":"13931_CR7","doi-asserted-by":"crossref","unstructured":"Hays, R. D. & Reeve, B. B. Measurement and modeling of health-related quality of life. in International Encyclopedia of Public Health (eds Killewo, J. & Heggenhougen, H. K.) 195\u2013205 (Elsevier Inc., (2008).","DOI":"10.1016\/B978-012373960-5.00336-1"},{"key":"13931_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bjid.2019.06.005","volume":"23","author":"BS Dutra","year":"2019","unstructured":"Dutra, B. S. et al. Changes health-related quality of life in HIV-infected patients following initiation of antiretroviral therapy: a longitudinal study. Brazilian J. Infect. Dis. 23, 211\u2013217 (2019).","journal-title":"Brazilian J. Infect. Dis."},{"key":"13931_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1186\/s12879-021-06851-9","volume":"21","author":"A Twimukye","year":"2021","unstructured":"Twimukye, A. et al. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infect. Dis. 21, 1154 (2021).","journal-title":"BMC Infect. Dis."},{"key":"13931_CR10","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2147\/PPA.S308571","volume":"15","author":"EA Mehari","year":"2021","unstructured":"Mehari, E. A., Muche, E. A., Gonete, K. A. & Shiferaw, K. B. Treatment satisfaction and its associated factors of dolutegravir based regimen in a resource limited setting. Patient Prefer Adherence. 15, 1177\u20131185 (2021).","journal-title":"Patient Prefer Adherence"},{"key":"13931_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/hiv.13352","volume":"24","author":"JA Brown","year":"2023","unstructured":"Brown, J. A. et al. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho. HIV Med. 24, 153\u2013162 (2023).","journal-title":"HIV Med."},{"key":"13931_CR12","doi-asserted-by":"crossref","unstructured":"Mellgren, \u00c5., Eriksson, L. E., Reinius, M., Marrone, G. & Svedhem, V. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish National registry study. PLoS One 15, (2020).","DOI":"10.1371\/journal.pone.0242710"},{"key":"13931_CR13","unstructured":"EuroQol Research Foundation. EQ-5D-3L User Guide. (2018)."},{"key":"13931_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse, D. J., Reynolds, I. I. I., Monk, C. F., Berman, T. H., Kupfer, D. J. & S. R. & The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 28, 193\u2013213 (1989).","journal-title":"Psychiatry Res."},{"key":"13931_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3889\/oamjms.2022.9293","volume":"10","author":"CN Dian","year":"2022","unstructured":"Dian, C. N., Effendy, E. & Amin, M. M. The validation of Indonesian version of patient health Questionnaire-9. Open. Access. Maced J. Med. Sci. 10, 193\u2013198 (2022).","journal-title":"Open. Access. Maced J. Med. Sci."},{"key":"13931_CR16","doi-asserted-by":"crossref","unstructured":"Kroenke, K., Spitzer, R. L. & Williams, J. B. W. The PHQ-9 Validity of a Brief Depression Severity Measure. J. GenIntern. Med. 16, 606\u2013613 (2001).","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"13931_CR17","first-page":"115","volume":"4","author":"M Zaccarelli","year":"2010","unstructured":"Zaccarelli, M., Bini, T. & Bai, F. One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects. PatientPreferenceandAdherence 4, 115\u2013125 (2010).","journal-title":"PatientPreferenceandAdherence"},{"key":"13931_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/life14030294","volume":"14","author":"CY Cheng","year":"2024","unstructured":"Cheng, C. Y., Wang, H. Y. & Yang, C. J. Self-Reported Health-Related quality of life and residual symptoms among virologically suppressed people living with HIV in the era of Single-Tablet regimens in taiwan: A Cross-Sectional study. Life 14, 294 (2024).","journal-title":"Life"},{"key":"13931_CR19","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10461-021-03515-2","volume":"26","author":"I Koga","year":"2022","unstructured":"Koga, I. et al. Factors associated with treatment satisfaction among people living with HIV in Japan and other selected countries: examination of the intertwined roles of medication, patient, and provider characteristics. AIDS Behav. 26, 1633\u20131651 (2022).","journal-title":"AIDS Behav."},{"key":"13931_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/QAD.0000000000002853","volume":"35","author":"G Guaraldi","year":"2021","unstructured":"Guaraldi, G. et al. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. AIDS 35, 939\u2013945 (2021).","journal-title":"AIDS"},{"key":"13931_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/QAD.0000000000002379","volume":"34","author":"JE Burns","year":"2020","unstructured":"Burns, J. E. et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. AIDS 34, 109\u2013114 (2020).","journal-title":"AIDS"},{"key":"13931_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/cid\/ciz853","volume":"71","author":"AM Kerchberger","year":"2020","unstructured":"Kerchberger, A. M. et al. Weight gain associated with integrase stand transfer inhibitor use in women. Clin. Infect. Dis. 71, 593\u2013600 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"13931_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann, C. et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 18, 56\u201363 (2017).","journal-title":"HIV Med."},{"key":"13931_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-019-0257-8","volume":"17","author":"P Chan","year":"2020","unstructured":"Chan, P. et al. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. AIDS Res. Ther. 17, 1 (2020).","journal-title":"AIDS Res. Ther."},{"key":"13931_CR25","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/ijerph16101772","volume":"16","author":"BX Tran","year":"2019","unstructured":"Tran, B. X. et al. Depression among patients with HIV\/AIDS: research development and effective interventions (gapresearch). Int. J. Environ. Res. Public. Health. 16, 1772 (2019).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"13931_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4172\/2155-9899.1000423","volume":"7","author":"Y Rivera Rivera","year":"2016","unstructured":"Rivera Rivera, Y. & Vazquez Santiago, F. J. Impact of depression and inflammation on the progression of HIV disease. J. Clin. Cell. Immunol. 7, 423\u2013416 (2016).","journal-title":"J. Clin. Cell. Immunol."},{"key":"13931_CR27","doi-asserted-by":"publisher","first-page":"e089783","DOI":"10.1136\/bmjopen-2024-089783","volume":"14","author":"M Guppy","year":"2024","unstructured":"Guppy, M. et al. Rate of decline in kidney function with age: a systematic review. BMJ Open. 14, e089783 (2024).","journal-title":"BMJ Open."},{"key":"13931_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/apc.2016.0286","volume":"31","author":"S Suzuki","year":"2017","unstructured":"Suzuki, S. et al. Effect of Tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-na\u00efve Asian patients: results from 12-year observational cohort. AIDS Patient Care STDS. 31, 105\u2013112 (2017).","journal-title":"AIDS Patient Care STDS"},{"key":"13931_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/0253-7184.68998","volume":"31","author":"AK Patel","year":"2010","unstructured":"Patel, A. K., Patel, K. K., Ranjan, R. R., Patel, A. R. & Patel, J. K. Tenofovir-associated renal dysfunction in clinical practice: an observational cohort from Western India. Indian J. Sex. Transm Dis. 31, 30\u201334 (2010).","journal-title":"Indian J. Sex. Transm Dis."},{"key":"13931_CR30","doi-asserted-by":"publisher","first-page":"e79885","DOI":"10.1371\/journal.pone.0079885","volume":"8","author":"D Mizushima","year":"2013","unstructured":"Mizushima, D. et al. WHO antiretroviral therapy guidelines 2010 and impact of Tenofovir on chronic kidney disease in Vietnamese HIV-infected patients. PLoS One. 8, e79885 (2013).","journal-title":"PLoS One"},{"key":"13931_CR31","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1097\/QAD.0000000000000347","volume":"28","author":"T Nishijima","year":"2014","unstructured":"Nishijima, T. et al. Long-term exposure to Tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS 28, 1903\u20131910 (2014).","journal-title":"AIDS"},{"key":"13931_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2174\/157016210793499259","volume":"8","author":"K Chaisiri","year":"2010","unstructured":"Chaisiri, K., Bowonwatanuwong, C., Kasettratat, N. & Kiertiburanakul, S. Incidence and risk factors for Tenofovir-Associated renal function decline among Thai HIV-Infected patients with Low-Body weight. Curr. HIV Res. 8, 504\u2013509 (2010).","journal-title":"Curr. HIV Res."},{"key":"13931_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s11904-021-00563-0","volume":"18","author":"DE Slawek","year":"2021","unstructured":"Slawek, D. E. People living with HIV and the emerging field of chronic pain\u2014what is known about epidemiology, etiology, and management. Curr. HIV\/AIDS Rep. 18, 436\u2013442 (2021).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"13931_CR34","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3390\/metabo12121202","volume":"12","author":"J Cusato","year":"2022","unstructured":"Cusato, J. et al. Dolutegravir discontinuation for neuropsychiatric symptoms in people living with HIV and their outcomes after treatment change: A Pharmacogenetic study. Metabolites 12, 1202 (2022).","journal-title":"Metabolites"},{"key":"13931_CR35","doi-asserted-by":"publisher","first-page":"101957","DOI":"10.1016\/j.jchemneu.2021.101957","volume":"114","author":"DN Jones","year":"2021","unstructured":"Jones, D. N. & Raghanti, M. A. The role of monoamine oxidase enzymes in the pathophysiology of neurological disorders. J. Chem. Neuroanat. 114, 101957 (2021).","journal-title":"J. Chem. Neuroanat."},{"key":"13931_CR36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1586\/14737175.8.5.781","volume":"8","author":"PB Wood","year":"2008","unstructured":"Wood, P. B. Role of central dopamine in pain and analgesia. Expert Rev. Neurother. 8, 781\u2013797 (2008).","journal-title":"Expert Rev. Neurother."},{"key":"13931_CR37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1186\/s12877-022-03480-y","volume":"22","author":"AK Goyal","year":"2022","unstructured":"Goyal, A. K. & Mohanty, S. K. Association of pain and quality of life among middle-aged and older adults of India. BMC Geriatr. 22, 939 (2022).","journal-title":"BMC Geriatr."},{"key":"13931_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neulet.2016.09.025","volume":"633","author":"Toshiyasu","year":"2016","unstructured":"Toshiyasu & Matsui Takahiro Nakata & Yasushi kobayashi. Localization of organic cation transporter 2 (OCT2) in monoaminergic and cholinergic axon terminals of the mouse brain. Neurosci. Letter. 633, 118\u2013124 (2016).","journal-title":"Neurosci. Letter"},{"key":"13931_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/mol.54.2.342","volume":"54","author":"AE Busch","year":"1998","unstructured":"Busch, A. E. et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. 54, 342\u2013352 (1998).","journal-title":"Mol. Pharmacol."},{"key":"13931_CR40","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neuroscience.2013.08.011","volume":"252","author":"T Nakata","year":"2013","unstructured":"Nakata, T. et al. Organic cation transporter 2 (SLC22A2), a low-affinity and high-capacity choline transporter, is preferentially enriched on synaptic vesicles in cholinergic neurons. Neuroscience 252, 212\u20132221 (2013).","journal-title":"Neuroscience"},{"key":"13931_CR41","first-page":"100782","volume":"33","author":"The Lancet Regional Health","year":"2023","unstructured":"The Lancet Regional Health \u2013 Western Pacific. Chronic pain in asia: we don\u2019t have to endure. Lancet Reg. Health West. Pac. 33, 100782 (2023).","journal-title":"Lancet Reg. Health West. Pac."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13931-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13931-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13931-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:18:17Z","timestamp":1757452697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13931-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13931"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13931-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29604"}}